Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.66 |
| ▸ | CNR2 | P34972 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.58 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.58 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.58 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.58 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.58 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217568 | 1.00 | CNR1 (0.66) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL31370880 | 0.94 | CNR1 (0.67) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL26114055 | 0.94 | CNR1 (0.67) | CNR1CNR2PSMB11PSMA7PSMB1 | |
| SCHEMBL26624415 | 0.89 | CNR1 (0.68) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL26624424 | 0.89 | CNR1 (0.68) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL29813833 | 0.89 | CNR1 (0.68) | CNR1CNR2ALDH1A1MAPTHPGD | |
| SCHEMBL42986 | 0.89 | HDAC1 (0.64) | CNR1CNR2ALDH1A1NPSR1HDAC1 | |
| SCHEMBL43741 | 0.89 | HDAC1 (0.64) | CNR1CNR2ALDH1A1NPSR1HDAC1 | |
| SCHEMBL2337076 | 0.87 | HDAC1 (0.66) | ALDH1A1NPSR1HDAC1HDAC6 | |
| SCHEMBL18220518 | 0.87 | HDAC1 (0.66) | ALDH1A1NPSR1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161436-B1 | Polyunsaturated fatty acid derivatives and their use in the treatment of cancer | ARDENIA INVESTMENTS LTD (GI) | 2003-06-25 | — | — | EP | disclosed |
| US-6403554-B2 | Polyunsaturated fatty acid derivatives and their use | ARDENIA INVESTMENTS LTD. (GI) | 2002-06-11 | — | — | US | disclosed |
| EP-1161436-A1 | POLYUNSATURATED FATTY ACID DERIVATIVES AND THEIR USE | Ardenia Investments Ltd. (GI) | 2001-12-12 | — | — | EP | disclosed |
| US-20010037032-A1 | Polyunsaturated fatty acid derivatives and their use | OASMIA PHARMACEUTICAL AB (SE) | 2001-11-01 | — | — | US | disclosed |
| US-6274747-B1 | COMPOUNDS CONTAINING A PHOSPHATE GROUP AND SECONDARY AMIDE GROUP; ANTICANCER AGENTS | ARDENIA INVESTMENTS LTD. (GI) | 2001-08-14 | — | — | US | disclosed |
| WO-2000047589-A1 | POLYUNSATURATED FATTY ACID DERIVATIVES AND THEIR USE | ARDENIA INVESTMENTS LTD. (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037032-A1 | Polyunsaturated fatty acid derivatives and their use | RXRA, RXRB, LPAR2 | CNR1 2108/4885CNR2 1192/4885ALDH1A1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.